Use of bisphosphonates in prostate cancer: Current status

Bisphosphonates are a relatively newer class of drugs which have been used for the prevention of skeletal related complications of age related osteoporosis or metastatic disease from carcinoma breast or multiple myeloma. Their role in the management of prostate cancer is still under evolution. We he...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Rishi Nayyar [verfasserIn] Narmada P Gupta [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2007

Schlagwörter:	Bisphosphonates prostate cancer hormone resistant prostate cancer

Übergeordnetes Werk:	In: Indian Journal of Urology - Wolters Kluwer Medknow Publications, 2017, 23(2007), 1, Seite 51-54
Übergeordnetes Werk:	volume:23 ; year:2007 ; number:1 ; pages:51-54

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.4103/0970-1591.30267

Katalog-ID:	DOAJ012777749

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ012777749
003	DE-627
005	20230310050650.0
007	cr uuu---uuuuu
008	230225s2007 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.4103/0970-1591.30267 \|2 doi
035			\|a (DE-627)DOAJ012777749
035			\|a (DE-599)DOAJ86848dd7cfd04538a848373dbdf56140
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC870-923
100	0		\|a Rishi Nayyar \|e verfasserin \|4 aut
245	1	0	\|a Use of bisphosphonates in prostate cancer: Current status
264		1	\|c 2007
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Bisphosphonates are a relatively newer class of drugs which have been used for the prevention of skeletal related complications of age related osteoporosis or metastatic disease from carcinoma breast or multiple myeloma. Their role in the management of prostate cancer is still under evolution. We hereby review the ongoing and some published randomized trials to define the role of bisphosphonates in various stages of prostate cancer.
650		4	\|a Bisphosphonates
650		4	\|a prostate cancer
650		4	\|a hormone resistant prostate cancer
653		0	\|a Diseases of the genitourinary system. Urology
700	0		\|a Narmada P Gupta \|e verfasserin \|4 aut
773	0	8	\|i In \|t Indian Journal of Urology \|d Wolters Kluwer Medknow Publications, 2017 \|g 23(2007), 1, Seite 51-54 \|w (DE-627)508330939 \|w (DE-600)2223236-9 \|x 19983824 \|7 nnns
773	1	8	\|g volume:23 \|g year:2007 \|g number:1 \|g pages:51-54
856	4	0	\|u https://doi.org/10.4103/0970-1591.30267 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/86848dd7cfd04538a848373dbdf56140 \|z kostenfrei
856	4	0	\|u http://www.indianjurol.com/article.asp?issn=0970-1591;year=2007;volume=23;issue=1;spage=51;epage=54;aulast=Nayyar \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/0970-1591 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1998-3824 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 23 \|j 2007 \|e 1 \|h 51-54

Indexfelder

author_variant	r n rn n p g npg
matchkey_str	article:19983824:2007----::sobshshntsnrsaeacr
hierarchy_sort_str	2007
callnumber-subject-code	RC
publishDate	2007
allfields	10.4103/0970-1591.30267 doi (DE-627)DOAJ012777749 (DE-599)DOAJ86848dd7cfd04538a848373dbdf56140 DE-627 ger DE-627 rakwb eng RC870-923 Rishi Nayyar verfasserin aut Use of bisphosphonates in prostate cancer: Current status 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Bisphosphonates are a relatively newer class of drugs which have been used for the prevention of skeletal related complications of age related osteoporosis or metastatic disease from carcinoma breast or multiple myeloma. Their role in the management of prostate cancer is still under evolution. We hereby review the ongoing and some published randomized trials to define the role of bisphosphonates in various stages of prostate cancer. Bisphosphonates prostate cancer hormone resistant prostate cancer Diseases of the genitourinary system. Urology Narmada P Gupta verfasserin aut In Indian Journal of Urology Wolters Kluwer Medknow Publications, 2017 23(2007), 1, Seite 51-54 (DE-627)508330939 (DE-600)2223236-9 19983824 nnns volume:23 year:2007 number:1 pages:51-54 https://doi.org/10.4103/0970-1591.30267 kostenfrei https://doaj.org/article/86848dd7cfd04538a848373dbdf56140 kostenfrei http://www.indianjurol.com/article.asp?issn=0970-1591;year=2007;volume=23;issue=1;spage=51;epage=54;aulast=Nayyar kostenfrei https://doaj.org/toc/0970-1591 Journal toc kostenfrei https://doaj.org/toc/1998-3824 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 23 2007 1 51-54
spelling	10.4103/0970-1591.30267 doi (DE-627)DOAJ012777749 (DE-599)DOAJ86848dd7cfd04538a848373dbdf56140 DE-627 ger DE-627 rakwb eng RC870-923 Rishi Nayyar verfasserin aut Use of bisphosphonates in prostate cancer: Current status 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Bisphosphonates are a relatively newer class of drugs which have been used for the prevention of skeletal related complications of age related osteoporosis or metastatic disease from carcinoma breast or multiple myeloma. Their role in the management of prostate cancer is still under evolution. We hereby review the ongoing and some published randomized trials to define the role of bisphosphonates in various stages of prostate cancer. Bisphosphonates prostate cancer hormone resistant prostate cancer Diseases of the genitourinary system. Urology Narmada P Gupta verfasserin aut In Indian Journal of Urology Wolters Kluwer Medknow Publications, 2017 23(2007), 1, Seite 51-54 (DE-627)508330939 (DE-600)2223236-9 19983824 nnns volume:23 year:2007 number:1 pages:51-54 https://doi.org/10.4103/0970-1591.30267 kostenfrei https://doaj.org/article/86848dd7cfd04538a848373dbdf56140 kostenfrei http://www.indianjurol.com/article.asp?issn=0970-1591;year=2007;volume=23;issue=1;spage=51;epage=54;aulast=Nayyar kostenfrei https://doaj.org/toc/0970-1591 Journal toc kostenfrei https://doaj.org/toc/1998-3824 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 23 2007 1 51-54
allfields_unstemmed	10.4103/0970-1591.30267 doi (DE-627)DOAJ012777749 (DE-599)DOAJ86848dd7cfd04538a848373dbdf56140 DE-627 ger DE-627 rakwb eng RC870-923 Rishi Nayyar verfasserin aut Use of bisphosphonates in prostate cancer: Current status 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Bisphosphonates are a relatively newer class of drugs which have been used for the prevention of skeletal related complications of age related osteoporosis or metastatic disease from carcinoma breast or multiple myeloma. Their role in the management of prostate cancer is still under evolution. We hereby review the ongoing and some published randomized trials to define the role of bisphosphonates in various stages of prostate cancer. Bisphosphonates prostate cancer hormone resistant prostate cancer Diseases of the genitourinary system. Urology Narmada P Gupta verfasserin aut In Indian Journal of Urology Wolters Kluwer Medknow Publications, 2017 23(2007), 1, Seite 51-54 (DE-627)508330939 (DE-600)2223236-9 19983824 nnns volume:23 year:2007 number:1 pages:51-54 https://doi.org/10.4103/0970-1591.30267 kostenfrei https://doaj.org/article/86848dd7cfd04538a848373dbdf56140 kostenfrei http://www.indianjurol.com/article.asp?issn=0970-1591;year=2007;volume=23;issue=1;spage=51;epage=54;aulast=Nayyar kostenfrei https://doaj.org/toc/0970-1591 Journal toc kostenfrei https://doaj.org/toc/1998-3824 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 23 2007 1 51-54
allfieldsGer	10.4103/0970-1591.30267 doi (DE-627)DOAJ012777749 (DE-599)DOAJ86848dd7cfd04538a848373dbdf56140 DE-627 ger DE-627 rakwb eng RC870-923 Rishi Nayyar verfasserin aut Use of bisphosphonates in prostate cancer: Current status 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Bisphosphonates are a relatively newer class of drugs which have been used for the prevention of skeletal related complications of age related osteoporosis or metastatic disease from carcinoma breast or multiple myeloma. Their role in the management of prostate cancer is still under evolution. We hereby review the ongoing and some published randomized trials to define the role of bisphosphonates in various stages of prostate cancer. Bisphosphonates prostate cancer hormone resistant prostate cancer Diseases of the genitourinary system. Urology Narmada P Gupta verfasserin aut In Indian Journal of Urology Wolters Kluwer Medknow Publications, 2017 23(2007), 1, Seite 51-54 (DE-627)508330939 (DE-600)2223236-9 19983824 nnns volume:23 year:2007 number:1 pages:51-54 https://doi.org/10.4103/0970-1591.30267 kostenfrei https://doaj.org/article/86848dd7cfd04538a848373dbdf56140 kostenfrei http://www.indianjurol.com/article.asp?issn=0970-1591;year=2007;volume=23;issue=1;spage=51;epage=54;aulast=Nayyar kostenfrei https://doaj.org/toc/0970-1591 Journal toc kostenfrei https://doaj.org/toc/1998-3824 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 23 2007 1 51-54
allfieldsSound	10.4103/0970-1591.30267 doi (DE-627)DOAJ012777749 (DE-599)DOAJ86848dd7cfd04538a848373dbdf56140 DE-627 ger DE-627 rakwb eng RC870-923 Rishi Nayyar verfasserin aut Use of bisphosphonates in prostate cancer: Current status 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Bisphosphonates are a relatively newer class of drugs which have been used for the prevention of skeletal related complications of age related osteoporosis or metastatic disease from carcinoma breast or multiple myeloma. Their role in the management of prostate cancer is still under evolution. We hereby review the ongoing and some published randomized trials to define the role of bisphosphonates in various stages of prostate cancer. Bisphosphonates prostate cancer hormone resistant prostate cancer Diseases of the genitourinary system. Urology Narmada P Gupta verfasserin aut In Indian Journal of Urology Wolters Kluwer Medknow Publications, 2017 23(2007), 1, Seite 51-54 (DE-627)508330939 (DE-600)2223236-9 19983824 nnns volume:23 year:2007 number:1 pages:51-54 https://doi.org/10.4103/0970-1591.30267 kostenfrei https://doaj.org/article/86848dd7cfd04538a848373dbdf56140 kostenfrei http://www.indianjurol.com/article.asp?issn=0970-1591;year=2007;volume=23;issue=1;spage=51;epage=54;aulast=Nayyar kostenfrei https://doaj.org/toc/0970-1591 Journal toc kostenfrei https://doaj.org/toc/1998-3824 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 23 2007 1 51-54
language	English
source	In Indian Journal of Urology 23(2007), 1, Seite 51-54 volume:23 year:2007 number:1 pages:51-54
sourceStr	In Indian Journal of Urology 23(2007), 1, Seite 51-54 volume:23 year:2007 number:1 pages:51-54
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Bisphosphonates prostate cancer hormone resistant prostate cancer Diseases of the genitourinary system. Urology
isfreeaccess_bool	true
container_title	Indian Journal of Urology
authorswithroles_txt_mv	Rishi Nayyar @@aut@@ Narmada P Gupta @@aut@@
publishDateDaySort_date	2007-01-01T00:00:00Z
hierarchy_top_id	508330939
id	DOAJ012777749
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ012777749</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310050650.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2007 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.4103/0970-1591.30267</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ012777749</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ86848dd7cfd04538a848373dbdf56140</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC870-923</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Rishi Nayyar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Use of bisphosphonates in prostate cancer: Current status</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2007</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Bisphosphonates are a relatively newer class of drugs which have been used for the prevention of skeletal related complications of age related osteoporosis or metastatic disease from carcinoma breast or multiple myeloma. Their role in the management of prostate cancer is still under evolution. We hereby review the ongoing and some published randomized trials to define the role of bisphosphonates in various stages of prostate cancer.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bisphosphonates</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prostate cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hormone resistant prostate cancer</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the genitourinary system. Urology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Narmada P Gupta</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Indian Journal of Urology</subfield><subfield code="d">Wolters Kluwer Medknow Publications, 2017</subfield><subfield code="g">23(2007), 1, Seite 51-54</subfield><subfield code="w">(DE-627)508330939</subfield><subfield code="w">(DE-600)2223236-9</subfield><subfield code="x">19983824</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:2007</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:51-54</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.4103/0970-1591.30267</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/86848dd7cfd04538a848373dbdf56140</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.indianjurol.com/article.asp?issn=0970-1591;year=2007;volume=23;issue=1;spage=51;epage=54;aulast=Nayyar</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0970-1591</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1998-3824</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">2007</subfield><subfield code="e">1</subfield><subfield code="h">51-54</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Rishi Nayyar
spellingShingle	Rishi Nayyar misc RC870-923 misc Bisphosphonates misc prostate cancer misc hormone resistant prostate cancer misc Diseases of the genitourinary system. Urology Use of bisphosphonates in prostate cancer: Current status
authorStr	Rishi Nayyar
ppnlink_with_tag_str_mv	@@773@@(DE-627)508330939
format	electronic Article
delete_txt_mv	keep
author_role	aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC870-923
illustrated	Not Illustrated
issn	19983824
topic_title	RC870-923 Use of bisphosphonates in prostate cancer: Current status Bisphosphonates prostate cancer hormone resistant prostate cancer
topic	misc RC870-923 misc Bisphosphonates misc prostate cancer misc hormone resistant prostate cancer misc Diseases of the genitourinary system. Urology
topic_unstemmed	misc RC870-923 misc Bisphosphonates misc prostate cancer misc hormone resistant prostate cancer misc Diseases of the genitourinary system. Urology
topic_browse	misc RC870-923 misc Bisphosphonates misc prostate cancer misc hormone resistant prostate cancer misc Diseases of the genitourinary system. Urology
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Indian Journal of Urology
hierarchy_parent_id	508330939
hierarchy_top_title	Indian Journal of Urology
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)508330939 (DE-600)2223236-9
title	Use of bisphosphonates in prostate cancer: Current status
ctrlnum	(DE-627)DOAJ012777749 (DE-599)DOAJ86848dd7cfd04538a848373dbdf56140
title_full	Use of bisphosphonates in prostate cancer: Current status
author_sort	Rishi Nayyar
journal	Indian Journal of Urology
journalStr	Indian Journal of Urology
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2007
contenttype_str_mv	txt
container_start_page	51
author_browse	Rishi Nayyar Narmada P Gupta
container_volume	23
class	RC870-923
format_se	Elektronische Aufsätze
author-letter	Rishi Nayyar
doi_str_mv	10.4103/0970-1591.30267
author2-role	verfasserin
title_sort	use of bisphosphonates in prostate cancer: current status
callnumber	RC870-923
title_auth	Use of bisphosphonates in prostate cancer: Current status
abstract	Bisphosphonates are a relatively newer class of drugs which have been used for the prevention of skeletal related complications of age related osteoporosis or metastatic disease from carcinoma breast or multiple myeloma. Their role in the management of prostate cancer is still under evolution. We hereby review the ongoing and some published randomized trials to define the role of bisphosphonates in various stages of prostate cancer.
abstractGer	Bisphosphonates are a relatively newer class of drugs which have been used for the prevention of skeletal related complications of age related osteoporosis or metastatic disease from carcinoma breast or multiple myeloma. Their role in the management of prostate cancer is still under evolution. We hereby review the ongoing and some published randomized trials to define the role of bisphosphonates in various stages of prostate cancer.
abstract_unstemmed	Bisphosphonates are a relatively newer class of drugs which have been used for the prevention of skeletal related complications of age related osteoporosis or metastatic disease from carcinoma breast or multiple myeloma. Their role in the management of prostate cancer is still under evolution. We hereby review the ongoing and some published randomized trials to define the role of bisphosphonates in various stages of prostate cancer.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1
title_short	Use of bisphosphonates in prostate cancer: Current status
url	https://doi.org/10.4103/0970-1591.30267 https://doaj.org/article/86848dd7cfd04538a848373dbdf56140 http://www.indianjurol.com/article.asp?issn=0970-1591;year=2007;volume=23;issue=1;spage=51;epage=54;aulast=Nayyar https://doaj.org/toc/0970-1591 https://doaj.org/toc/1998-3824
remote_bool	true
author2	Narmada P Gupta
author2Str	Narmada P Gupta
ppnlink	508330939
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.4103/0970-1591.30267
callnumber-a	RC870-923
up_date	2024-07-03T13:58:51.995Z
_version_	1803566587047837696
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ012777749</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310050650.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2007 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.4103/0970-1591.30267</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ012777749</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ86848dd7cfd04538a848373dbdf56140</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC870-923</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Rishi Nayyar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Use of bisphosphonates in prostate cancer: Current status</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2007</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Bisphosphonates are a relatively newer class of drugs which have been used for the prevention of skeletal related complications of age related osteoporosis or metastatic disease from carcinoma breast or multiple myeloma. Their role in the management of prostate cancer is still under evolution. We hereby review the ongoing and some published randomized trials to define the role of bisphosphonates in various stages of prostate cancer.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bisphosphonates</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prostate cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hormone resistant prostate cancer</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the genitourinary system. Urology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Narmada P Gupta</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Indian Journal of Urology</subfield><subfield code="d">Wolters Kluwer Medknow Publications, 2017</subfield><subfield code="g">23(2007), 1, Seite 51-54</subfield><subfield code="w">(DE-627)508330939</subfield><subfield code="w">(DE-600)2223236-9</subfield><subfield code="x">19983824</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:2007</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:51-54</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.4103/0970-1591.30267</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/86848dd7cfd04538a848373dbdf56140</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.indianjurol.com/article.asp?issn=0970-1591;year=2007;volume=23;issue=1;spage=51;epage=54;aulast=Nayyar</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0970-1591</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1998-3824</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">2007</subfield><subfield code="e">1</subfield><subfield code="h">51-54</subfield></datafield></record></collection>
score	7.4020357

Nicht das Richtige dabei?

Schreiben Sie uns!

Use of bisphosphonates in prostate cancer: Current status

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?